@article {15524, title = {Still hope for schistosomiasis vaccine}, journal = {Human Vaccines and Immunotherapeutics}, volume = {11}, number = {10}, year = {2015}, note = {Journal Article
Research Support, Non-U.S. Gov{\textquoteright}t
United States}, pages = {2504-8}, abstract = {Schistosomiasis is a parasitic disease caused by helminths belonging to the Schistosoma genus. Approximately 700 million people are at risk of infection and 200 million people are currently infected. Schistosomiasis is the most important helminth infection, and treatment relies solely on the drug praziquantel. Worries of praziquantel resistance as well as high disease burden are only some of the justifications which support the development of a vaccine against schistosomiasis. To date, only 2 schistosome vaccines have made it into clinical trials: Sh28GST (Bilhvax) and Sm14. However, there are several vaccine candidates, such as TSP-2, sm-p8, and Sm-Cathepsin B, which are generating promising results in pre-clinical studies. Schistosomiasis vaccine development has been an uphill battle, and there are still several hurdles to overcome in the future. Fortunately, the research groups involved in the research for vaccine development have not abandoned their work. Furthermore, in the last few years, schistosomiasis has garnered some additional attention on a global scale due to its significant impact on public health.}, keywords = {Animals, Antigens, Helminth/*immunology, Drug Discovery/methods/trends, Humans, Schistosoma/*immunology, Schistosomiasis/immunology/*prevention \& control, Vaccines/*immunology/*isolation \& purification}, isbn = {2164-554X (Electronic)
2164-5515 (Linking)}, author = {Ricciardi, A. and Ndao, M.} }